both report associations of genetic polymorphisms of the 2-adrenergic receptor with response to albuterol. However, the approach of these two groups differs significantly by genotyping either single nucleotide polymorphisms (SNPs) in isolation or multiple phased SNPs arranged on the same chromosome (haplotype). This has led to discordant results between the two studies. Drysdale Drysdale et al. first identify 13 SNPs in a region spanning 1.6 kb of the 2 AR gene. They find that only 12 distinct haplotypes are represented in a population of four major ethnic groups, out of 8096 possible haplotypes representing all combinations of SNPs on a single chromosome. Moreover, only five of these haplotype pairs (one haplotype per chromosome) are common in an asthmatic cohort. Drysdale et al 1 assess the bronchodilator response to albuterol in asthmatics to determine the relevance of the common haplotype pairs. Each haplotype pair is linked to clear differences in the in vivo response to 2 AR agonist, whereas there is no association between the response to albuterol and any individual SNP.
Differences in the experimental conditions used may account for discrepancies in the two papers. To begin with, the subject groups utilized in the two studies are different. Martinez I do not think that the more recent Drysdale study necessarily invalidates the Martinez study. The two studies examine different subject groups and report the findings they obtain from assessing these subject groups. Martinez et al 2 based their study on previous clinical and biochemical work describing polymorphisms in the 2 AR gene. 3, 4 These authors focused on the question whether two different polymorphisms, at amino acids 16 and 27, were associated with differential responses to 2 AR agonists. Drysdale et al 1 sought to assess the relevance of combinations of multiple SNPs, or specific haplotypes, in a span of the 2 AR gene for predicting the bronchodilator response to agonists.
Possibly, the discrepant results of the authors can at least in part be attributed to different subject groups. To begin with, Martinez et al 1 utilize a population that exclusively consists of children. It is possible that the mechanisms by which 2 AR polymorphisms determine responsiveness to agonists in children may differ from those in adults. These children are of Caucasian, Hispanic, or mixed background. On the other hand, Drysdale et al 2 assess bronchodilatory response in an asthmatic cohort of 121 Caucasian, asthmatic patients and identify the most common haplotype pairs present in the cohort. By assessing the predictive value of these haplotypes in response to albuterol the authors find that haplotype pair is significantly related to improvements in FEV1. In contrast to the Martinez results, no association was observed between the response to albuterol and any individual SNP. It is worth noting that these results are based on 121 Caucasian, asthmatic individuals. It is possible that different haplotypes are prevalent in other ethnic populations, which would confound any predictions among ethnic groups based on haplotype. In addition, perhaps results would differ if a mixed nonasthmatic/asthmatic population were studied. However, it should be noted that most of the subjects in the Martinez study were also Caucasian, and therefore, these discrepancies are not readily resolved in terms of different patient populations alone. Furthermore, Martinez observes similar trends for asthmatic and non-asthmatic children. However, similar trends may not be observed for asthmatic and non-asthmatic adults used in the Drysdale study. that cannot be readily resolved with the available information. Rather than assuming one study invalidates the other, both studies may have limitations imposed by the method of genotyping. Use of only one or two polymorphisms negates the possibility of significant interactions among SNPs in a given haplotype, whereas use of haplotypes may be confounded by variable prevalence among ethnic patient populations. It is prudent to examine carefully the subject groups and methods employed by the authors to better appreciate the strengths and weaknesses of the two studies and to evaluate the use of haplotype analysis in pharmacogenetic studies.
